EP2822530A1 - Kit comprenant deux compositions séparées, notamment pour une application cosmétique - Google Patents
Kit comprenant deux compositions séparées, notamment pour une application cosmétiqueInfo
- Publication number
- EP2822530A1 EP2822530A1 EP13708186.5A EP13708186A EP2822530A1 EP 2822530 A1 EP2822530 A1 EP 2822530A1 EP 13708186 A EP13708186 A EP 13708186A EP 2822530 A1 EP2822530 A1 EP 2822530A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- kit according
- capsule
- viscosity
- capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
Definitions
- Kit comprising two separate compositions, in particular for a cosmetic application
- the present invention relates to a kit comprising two separate compositions, in particular for a cosmetic application.
- compositions comprising capsules, used in many technical fields. These capsules are generally formed of a heart surrounded by a more or less solid envelope.
- the capsules are in particular filled with biologically or cosmetically active products. They are used in particular to protect their contents and control the release of the product they contain.
- Such capsules are also used in biochemical applications to immobilize cells in bioreactors or as artificial cells in implants.
- such capsules are used to contain various additives that improve the properties of a food product, such as its taste, or shelf life.
- the capsule casings are generally formed of a biocompatible material with the human body. These envelopes must be broken in order to release the active ingredients contained in the capsules. It is therefore necessary that they are sufficiently fragile so that the consumer can easily break the capsules during their use.
- a reagent which, in contact with the envelope, triggers a mechanism leading to its rupture.
- it may be useful to make available to the consumer both capsules containing a given active ingredient and a reagent for breaking these capsules, so that it can prepare itself the composition to use.
- the present invention aims to provide a system for a simple and quick application for the user of active compounds, in particular present in capsules.
- the present invention also aims to provide a system for obtaining a product, including cosmetic, with a satisfactory visual appearance and texture.
- the present invention relates to a kit comprising two separate compositions (A) and (B), wherein:
- composition (A) is an aqueous gel with a viscosity of less than 1 1 Pa.s, advantageously of from 1 to 10 Pa.s, said composition (A) containing at least one capsule comprising:
- a liquid heart comprising at least one active agent
- composition (B) comprises a depolymerizing agent.
- compositions means distinct compositions, for example placed in different compartments.
- the compositions (A) and (B) are arranged in the same kit, but can not come into contact in the kit.
- the compositions (A) and (B) are therefore distinct entities.
- the kit comprises a composition (A) in the form of an aqueous gel.
- aqueous gel a solution comprising water and a gelling agent.
- the weight percentage of water of the aqueous gel is at least 70%, especially 70% to 85%, preferably 70% to 80%, relative to the total mass of the composition (A) .
- gelling agent means a compound capable of giving a composition the consistency of a gel.
- gel means a three-dimensional network of solids diluted in a fluid, which may have properties ranging from soft and ductile to hard and brittle, with a viscosity typically less than 20 Pa.s, advantageously less than 15 Pa.s, and preferably less than 10 Pa.s.
- the gelling agent is preferably selected from the group consisting of polysaccharides, galactomannans, polysaccharides, glycosaminoglycans and polyols.
- xanthan is chosen from the group consisting of xanthan, carrageenan, carob, guar, gellan, hyaluronic acid, glycerol, propanediol or cellulose derivatives.
- the aqueous gel serves as a dispersion medium for the capsule and ensures permanent hydration of its gelled envelope.
- the viscosity of the aqueous gel is less than 1 1 Pa.s, advantageously from 1 to 10 Pa.s.
- the viscosity of the aqueous gel is preferably greater than 2 Pa., Preferably less than 10 Pa.s, advantageously less than 8 Pa.s, for example between 2 Pa.s and 8 Pa.s.
- the viscosity of the aqueous gel is preferably from 1 to 10 Pa.s.
- the viscosity of the aqueous gel is preferably from 2 to 10 Pa.s.
- the viscosity of the aqueous gel is measured at 25 ° C.
- the viscosity is measured by the following method.
- a Brookfield type viscometer is used, typically a Brookfield RVDV-E digital viscometer (spring torque of 7187.0 dyne-cm), which is a rotational speed viscometer equipped with a spindle.
- a speed is imposed on the mobile in rotation and the measurement of the torque exerted on the mobile makes it possible to determine the viscosity knowing the geometry / shape parameters of the mobile used.
- a size mobile (No.) 05 (Brookfield reference: RV5) is used.
- the shear rate corresponding to the measurement of the viscosity is defined by the mobile used and the speed of rotation thereof.
- Such viscosity of the aqueous gel allows a good suspension of the capsule, especially over a period of at least one month, at a temperature of 40 ° C. It also allows, during the mixing of the composition (A) with the composition (B), to obtain a depolymerization kinetics of the envelope of about a few seconds or about thirty minutes or even one hour.
- the aqueous gel must not comprise any compound capable of depolymerizing the gelled envelope of the capsule in order to keep the capsule intact until the step of mixing the compositions (A) and (B) of the kit according to the invention.
- the aqueous gel is transparent so that the consumer can visualize the capsule. Its texture is chosen according to the texture that one wishes to obtain for the final product, resulting from the mixture of the two compositions (A) and (B).
- the composition (A) comprises at least one capsule containing a liquid heart comprising at least one active agent, and a gelled envelope completely encapsulating the liquid heart to retain the liquid heart.
- composition (A) may comprise a single capsule or a plurality of identical or different capsules.
- liquid heart means a liquid internal phase at least partially surrounded by an external phase.
- the liquid internal phase may especially be in the form of a solution, an emulsion or a suspension.
- the liquid heart of the capsule comprises at least one active agent.
- the liquid heart may comprise a single active agent or a mixture of several active agents.
- active agent means a compound having a physiological effect beneficial on the element on which it acts. It aims for example to protect, maintain in good condition, cure, heal, perfume, flavor or color.
- the active agent is advantageously a cosmetic, dermopharmaceutical, pharmaceutical or food agent.
- the liquid core may contain the active agent in the form of a pure liquid, or a solution of the active agent in a liquid solvent, or a dispersion such as an emulsion or suspension of the active agent in a liquid.
- the active agent when it is a cosmetic agent, it may be chosen from sodium hyaluronate or other moisturizing / repairing molecules, vitamins, enzymes, anti-wrinkle, anti-aging, protective / antiradical agents, antioxidants, soothing, softening, anti-irritant, tensing / smoothing, emollient, slimming, anti-cellulite, firming, shaping, draining, anti-inflammatory, depigmenting, whitening, self-tanning, exfoliating, stimulating cell renewal or stimulating cutaneous microcirculation, absorbing or filtering UV, anti-dandruff.
- sodium hyaluronate or other moisturizing / repairing molecules vitamins, enzymes, anti-wrinkle, anti-aging, protective / antiradical agents, antioxidants, soothing, softening, anti-irritant, tensing / smoothing, emollient, slimming, anti-cellulite, firming, shaping, draining, anti-inflammatory, depigmenting, whitening,
- a cosmetic agent that may be contained in the heart is for example cited in Council Directive 93/35 / EEC dated June 14, 1993.
- This product is for example a cream, an emulsion, a lotion, a gel and an oil for skin (hands, face, feet, etc.), a foundation (liquid, paste) a preparation for baths and showers (salts, mousses, oils, gels, etc.), a hair care product (hair dyes and bleaches ), a cleaning product (lotions, powders, shampoos), a hair care product (lotions, creams, oils), a styling product (lotions, lacquers, glossines), a product for shaving (soaps, mousses, lotions, etc.), a product intended to be applied to the lips, a sun product, a tanning product without sun, a product for whitening the skin, an anti-wrinkle product.
- the dermopharmaceutical agents more particularly designate agents acting on the skin.
- the active agent is a pharmaceutical agent
- it is advantageously chosen from anticoagulants, anti-thrombogenic agents, anti-mitotic agents, anti-proliferation agents, anti-adhesion agents, anti-migration agents, cell adhesion promoters, growth, antiparasitic molecules, anti-inflammatories, angiogenics, angiogenesis inhibitors, vitamins, hormones, proteins, antifungals, antimicrobial molecules, antiseptics or antibiotics.
- the liquid core contains reagents such as proteins or reagents to form a bioreactor, to immobilize cells in bioreactors or to form artificial cells for implants.
- reagents such as proteins or reagents to form a bioreactor, to immobilize cells in bioreactors or to form artificial cells for implants.
- the food agents are advantageously purees of vegetables or fruits such as mango puree, pear puree, coconut puree, cream of onions, leeks, carrots, or other preparations that may mix several fruits or vegetables.
- these are oils such as a food oil, such as olive oil, soybean oil, grape seed oil, sunflower oil, or any other oil extracted from the plants, as well as active ingredients.
- probiotics, yeasts, vitamins, minerals or oleoactives are examples of vegetables or fruits such as mango puree, pear puree, coconut puree, cream of onions, leeks, carrots, or other preparations that may mix several fruits or vegetables.
- oils such as a food oil, such as olive oil, soybean oil, grape seed oil, sunflower oil, or any other oil extracted from the plants, as well as active ingredients.
- probiotics, yeasts, vitamins, minerals or oleoactives such as probiotics, yeasts, vitamins, minerals or oleoactives.
- the term “gelled envelope” means an external phase at least partially surrounding an internal phase, and comprising a compound in the gelled state or in gel form.
- the gelled envelope is an aqueous phase, and typically a hydrogel of the polyelectrolyte in the gelled state.
- the gelled envelope may also be referred to as "membrane" or "bark”.
- the gelled envelope of the capsule has a thickness of less than 500 ⁇ , advantageously greater than 10 ⁇ .
- the gelled envelope is generally formed by a monolayer of a homogeneous material.
- the gelled envelope of the capsule comprises a gel containing water and a polyelectrolyte advantageously chosen from proteins, natural polysaccharides and polyelectrolytes reactive with multivalent ions.
- a polyelectrolyte reactive with polyvalent ions means a polyelectrolyte capable of passing from a liquid state in an aqueous solution to a gelled state under the effect of contact with a gelling solution containing multivalent ions such as alkaline earth metal ions selected for example from calcium ions, barium ions, magnesium ions.
- the individual polyelectrolyte chains are substantially free to flow relative to one another.
- An aqueous solution of 2% by weight of polyelectrolyte then exhibits a purely viscous behavior at the shear gradients characteristic of the forming process.
- the viscosity of this solution with zero shear is between 50 mPa.s and 10,000 mPa.s, advantageously between 3000 mPa.s and 7000 mPa.s.
- This viscosity at shear gradients characteristic of the flows involved during the manufacture of the capsules is for example, measured using a stress rheometer, or deformation, imposed at the manufacturing temperature, 25 ° C for example.
- a cone-plane geometry with a diameter of 10 to 50 mm and a cone angle of 2 ° maximum will be used.
- the individual polyelectrolyte chains in the liquid state advantageously have a molar mass greater than 65000 g / mol.
- the individual polyelectrolyte chains together with the multivalent ions form a coherent three-dimensional network which holds the liquid core and prevents its flow.
- the individual chains are held together and can not flow freely relative to each other.
- the viscosity of the formed gel is infinite.
- the gel has a threshold of stress to the flow. This stress threshold is greater than 0.05 Pa.
- the gel also has a modulus of elasticity that is non-zero and greater than 35 kPa.
- the three-dimensional polyelectrolyte gel contained in the envelope traps water and the surfactant when present.
- the mass content of the polyelectrolyte in the envelope is, for example, from 0.5% to 5% relative to the total mass of the envelope.
- the polyelectrolyte is preferably a biocompatible polymer that is harmless to the human body. It is for example produced biologically.
- polysaccharides synthetic polyelectrolytes based on acrylates (sodium, lithium, potassium or ammonium polyacrylate, or polyacrylamide), synthetic polyelectrolytes based on sulfonates (poly (styrene sulfonate) ) of sodium, for example). More particularly, the polyelectrolyte is selected from alkaline earth alginates, such as sodium alginate or potassium alginate, gellan or pectin.
- the polyelectrolyte is a sodium alginate.
- Alginates are produced from brown algae called “laminar”, referred to as “sea weed”.
- Such alginates advantageously have a content of ⁇ -L-guluronate greater than about 50%, preferably greater than 55%, or even greater than 60%.
- the gelled envelope may further contain a surfactant.
- the surfactant is preferably an anionic surfactant, a nonionic surfactant, a cationic surfactant or a mixture thereof.
- the molecular weight of the surfactant is between 150 g / mol and 10,000 g / mol, advantageously between 250 g / mol and 1500 g / mol.
- the surfactant is an anionic surfactant
- it is for example chosen from alkyl sulphates, alkyl sulphonates, alkyl aryl sulphonates, alkaline alkyl phosphates, dialkyl sulphosuccinates and alkaline earth salts of saturated or unsaturated fatty acids.
- These surfactants advantageously have at least one hydrophobic hydrocarbon chain having a number of carbons greater than 5 or even 10 and at least one hydrophilic anionic group, such as a sulphate, a sulphonate or a carboxylate linked to one end of the hydrophobic chain.
- the surfactant is a cationic surfactant
- it is for example chosen from alkylpyridium or alkylammonium halide salts such as n-ethyldodecylammonium chloride or bromide, cetylammonium chloride or bromide (CTAB) .
- CTLAB cetylammonium chloride or bromide
- These surfactants advantageously have at least one hydrophobic hydrocarbon chain having a number of carbon atoms greater than 5 or even 10 and at least one hydrophilic cationic group, such as a quaternary ammonium cation.
- the surfactant is a nonionic surfactant
- it is for example chosen from polyoxyethylenated and / or polyoxypropylenated derivatives of fatty alcohols, fatty acids, or alkylphenols, arylphenols, or from alkylglucosides, polysorbates, cocamides.
- the surfactant is sodium lauryl sulphate (SLS or SDS).
- the mass content of surfactant in the shell is greater than 0.001% and is advantageously greater than 0.1%.
- the capsule has a substantially spherical shape and an outside diameter greater than 0.5 mm, advantageously less than 10 mm and preferably between 1 and 5 mm. It may also be referred to as "pearl”.
- the capsule is a so-called "simple" capsule, meaning that the liquid core, viscous or thixotropic, consists of a single internal phase, the internal phase being placed in contact with the gelled envelope.
- a simple capsule is for example a capsule as described in the international application WO 2010/063937 in the name of the Applicant.
- a single capsule therefore comprises two distinct phases, a liquid internal phase and an external phase in the gelled state surrounding the internal phase.
- the active agent is then contained in the internal phase.
- the capsule is a capsule called "complex", meaning that the liquid heart, viscous or thixotropic, has a single intermediate drop of an intermediate phase, the intermediate phase being placed in contact with the gelled envelope , and at least one internal drop of an internal phase disposed in the intermediate drop.
- the liquid core of a complex capsule may thus comprise a continuous intermediate phase in which there is only one drop of internal phase.
- the liquid core comprises a continuous intermediate phase in which there is a plurality of drops of internal phase (s).
- the active agent of the liquid heart may be contained in the intermediate phase and / or in the internal phase of the liquid heart.
- the complex capsules have in particular a monodisperse distribution.
- the polydispersity in size of the complex capsules measured by the coefficient of variation C v consisting of the ratio of the standard deviation on the average, is less than 10%, and in particular between 1% and 10%.
- This ratio can be measured for example on the basis of the diameters measured on at least seven capsules using the image processing software "Image J”, on the basis of a snapshot of the capsules taken in top view with a digital camera.
- the bulk polydispersity of the capsules can be calculated on the basis of at least fifty measurements of the mass of fifty complex capsules made using a Mettler-Toledo type balance with an accuracy of 0.1 mg .
- the liquid core of a complex capsule comprises an intermediate drop formed based on an intermediate phase and at least one macroscopic internal drop disposed in the intermediate drop and formed of an internal phase substantially immiscible with the intermediate phase.
- the intermediate phase is for example made based on an aqueous or oily solution.
- the flow viscosity of the intermediate phase measured under the conditions involved during the formation of the complex capsules, is substantially lower, for example at least 5% less than the viscosity of the solution intended to form the gelled envelope.
- This viscosity at the shear gradients characteristic of the flows involved during the manufacture of the capsules is for example measured using a stress-strain rheometer, or deformation, imposed at the manufacturing temperature, for example 25 ° C.
- a cone-plane geometry with a diameter of 10 to 50 mm and a cone angle of 2 ° maximum will be used.
- the intermediate drop of the liquid heart is advantageously liquid.
- the intermediate drop is made based on a thixotropic intermediate phase, which is in the liquid state and destructured when it flows, but which is substantially solid or gelled at rest.
- liquid as it flows it is meant that the behavior of the intermediate phase is viscous, ie the deformation of the material depends not only on the applied stress but also on the duration during which this stress is applied. .
- One way to characterize this behavior is by a creep test using a rheometer on the sample, we apply a characteristic stress of the flows involved during the manufacturing and we trace the strain curve as a function of time ( data obtained with the rheometer software). If the curve has a non-zero slope at long times (more than 30 seconds), the intermediate phase can be considered as being liquid. If this slope is zero, the intermediate phase can be considered as solid.
- solid or gelled at rest it is meant that the behavior of the solid intermediate phase or gelled at rest, ie the deformation of the material depends only on the applied stress.
- One way of characterizing this behavior is by a creep test using a rheometer, on the sample, a stress is applied characteristic of those undergone by the capsule at rest as a function of time (data obtained with the software of the rheometer). If the curve has a zero slope at long times (more than 30 seconds), the intermediate phase can be considered as solid. If this slope is non-zero, the intermediate phase can be considered as being liquid.
- the intermediate drop is gelled.
- the intermediate drop is for example formed by the gelling of a gelling product obtained by a temperature change, in particular by a temperature decrease of at least 10 ° C.
- gelation is obtained in the presence of ions, other molecules or certain conditions of pH or ionic strength.
- the intermediate drop may comprise one or more cosmetic, dermo-pharmaceutical, pharmaceutical or food active agents, as defined above.
- the intermediate drop may also include excipients, such as thickeners, or rheology modifiers.
- thickeners are, for example, polymers, cross-polymers, microgels, gums or proteins, including polysaccharides, celluloses, polysaccharides, silicone polymers and co-polymers, colloidal particles (silica, clays). , latex ).
- the intermediate drop may comprise solid particles, and in particular nacre particles.
- the intermediate drop is fully interposed between the inner drop and the gelled envelope.
- the entire inner surface of the gelled envelope is in contact with the intermediate drop, so that the intermediate drop keeps the inner drop completely away from the gelled envelope.
- the capsule advantageously comprises at least two internal drops arranged in the intermediate drop, each internal drop comprising an internal phase, advantageously less than twenty internal drops arranged in the intermediate phase, advantageously less than five internal drops arranged in the intermediate phase, and especially of one to four internal drops arranged in the intermediate phase.
- the capsule comprises two internal drops arranged in the intermediate phase.
- These two internal drops may in particular have internal phases of distinct compositions.
- the internal drops are macroscopic.
- the maximum transverse dimension of each internal drop given by its diameter when it is spherical, is greater than 150 ⁇ , and is in particular greater than 300 ⁇ . These dimensions are measured by the method using the "Image J" image processing software described above.
- the minimum volume of at least one internal drop is thus greater than 0.5% of the volume of the heart.
- the sum of the volumes of the or each internal drop is thus comprised from 0.5% to 65% of the total volume of the heart, in particular from 1% to 55% of the volume of the heart.
- Each internal drop advantageously has a spherical shape.
- the shape of the inner drop is different from a spherical shape, for example elliptical or lenticular.
- the internal phase constituting the internal drops is substantially immiscible with the intermediate phase constituting the intermediate drops.
- the internal phase When the intermediate phase is aqueous, the internal phase is oily, and conversely when the intermediate phase is oily, the internal phase is aqueous.
- the viscosity of the internal phase forming the internal drop is, for example, less than 10% of the viscosity of the intermediate phase at the characteristic shear gradients involved in the drop formation process, ie a viscosity of approximately 1000 mPa. s.
- This viscosity at the shear gradients characteristic of the flows involved during the manufacture of the capsules is for example measured using a stress-strain rheometer, or deformation, imposed at the manufacturing temperature, for example 25 ° C.
- a cone-plane geometry with a diameter of 10 to 50 mm and a cone angle of 2 ° maximum will be used.
- the gelled envelope of the complex capsules is such that the volume ratio R v of the volume of the liquid core to the volume of the gelled envelope is greater than 2, and is in particular greater than 5.
- This ratio R v is advantageously less than 50 It is for example between 5 and 10.
- the thickness of the gelled envelope of the complex capsules is in particular less than 300 ⁇ , and is for example between 25 and 100 ⁇ .
- the kit comprises a composition (B) comprising a depolymerizing agent.
- depolymerizing agent means a compound capable of embrittling and / or breaking the gelled envelope of the capsule to allow the release of the liquid core in the aqueous gel.
- Composition (B) may also be referred to as "depolymerizing solution” or “depolymerizing composition”.
- the depolymerizing agent is a compound capable of chelating the ions capable of forming the gel of the envelope.
- These compounds are capable of forming very stable metal complexes. They are suitable for being bound to metal cations in the form of one of its conjugate bases.
- EDTA ethylene diamine tetraacetic acid
- EGTA ethylene glycol tetraacetic acid
- crown ethers such as 1, 13-diaza-21-crown-7 or 1 , 10-diaza-18-crown-6
- cryptands or else acids such as citric acid, acrylic acid, polyacrylic acid, phytic acid, phosphoric acid, tartaric acid, malic acid, or more generally a polyacid, their inorganic salts, such as a sodium or potassium salt, or their esters.
- the depolymerizing agent is a polymer or a copolymer comprising at least one monomer having a free acid function after polymerization.
- the depolymerizing agent is for example chosen from polymers or copolymers of acrylic acid, methacrylic acid, crotonic acid and maleic acid, their salts or their esters.
- the depolymerizing agent may also be a salt capable of being exchanged with the ions capable of forming the gel of the envelope.
- the depolymerizing agent is chosen from monovalent cations of monovalent anions.
- the depolymerizing agent is citric acid or a salt thereof.
- the depolymerizing agent is, for example, sodium citrate dihydrate.
- the mass concentration of chelating compound is in particular greater than 0.5% and is for example from 2% to 30% relative to the total mass of the composition (B).
- the depolymerizing agent is an enzyme capable of degrading the proteins or polysaccharides.
- the contacting and mixing of the compositions (A) and (B) trigger the depolymerization of the gelled envelope of the capsule by the depolymerizing agent.
- the interchain links at the origin of the three-dimensional network constituting the envelope break up progressively.
- the envelope then moves from the gelled state to the liquid state, thereby releasing the liquid core from the capsule in the aqueous gel.
- the mixing time of the compositions (A) and (B) required to obtain a homogeneous final product free of capsule shell residues is directly determined by the depolymerization kinetics.
- the mixing time is less than one hour, advantageously between 1 second and 30 minutes, and preferably between 5 seconds and 10 minutes.
- the mixing time depends on various parameters, in particular the viscosities of the compositions (A) and (B), the effectiveness of the depolymerizing agent vis-à-vis the gelled envelope of the capsules, but also the characteristics of the capsules (size, composition, thickness of the envelope, etc.).
- the polyelectrolyte of the capsule of the composition (A) is chosen from calcium ion-reactive polyelectrolytes, such as sodium alginate, and the depolymerizing agent of the composition (B) is chosen from among the calcium chelating agents and calcium-exchangeable salts, such as EDTA.
- the polyelectrolyte of the capsule of the composition (A) is collagen and the depolymerizing agent is chosen from enzymes capable of degrading proteins, such as Aquabeautine, papain or pepsin.
- the composition (B) of the kit according to the invention has a viscosity of from 1 mPa.s to 100 Pa.s, advantageously from 1 mPa.s to 60 Pa.s.
- the texture of the composition (B) is chosen according to the texture that is desired for the final product.
- composition (B) is in particular in the form of a liquid solution, a gel, a cream, a foam or an emulsion. Its visual appearance partly determines the visual appearance of the final product.
- the composition (B) contains a mass percentage of water of at least 60%, advantageously from 70% to 95%, preferably from 75% to 95%, relative to the total weight of said composition.
- composition (B) additionally contains one or more active agents chosen from cosmetic, dermo-pharmaceutical, pharmaceutical or food agents, as defined above.
- the invention also relates to an application of compositions (A) and (B) of the kit according to the invention.
- the invention therefore also relates to the kit as defined above for its use for simultaneous or separate application over time, especially on the skin, of compositions (A) and (B) as defined above.
- the kit of the invention therefore makes it possible to apply the compositions (A) and (B) as defined above simultaneously, that is to say together, or one after the other.
- compositions (A) and (B) are applied simultaneously.
- the composition (A) is for example arranged in a first container and the composition (B) in a second container distinct from the first.
- the two compositions are combined in the same container, put in contact and mixed.
- the product obtained by this process is ready to be applied.
- the consumer takes for example a given amount of the composition (A) and deposits it in a container. It then takes a given amount of the composition (B), separated from the composition (A) in the kit, and deposits it in the same container. He puts the two compositions in contact and mixes them together. The product obtained is then ready to be applied, for example on the skin, by the consumer himself. It is therefore a simultaneous application.
- Said container may be in various forms, it is for example a cup, a pot, a bottle, a tube or a bottle.
- the mixture can be done by hand, with a spoon, with or without agitation of the container for example.
- a kit for simultaneous application of the compositions is for example a cosmetic kit in which the composition (A) is initially placed in a pot and the composition (B) in a cup or a tube. The consumer pours the composition (B) into the pot where the composition is (A) and mixed with a spoon until a homogeneous composition. He can then apply it as a classic cosmetic product. According to another embodiment, the consumer takes and applies one of the two compositions of the kit, then takes and applies the other composition in order to mix with the first and to obtain the final product. It is then a separate application in time.
- a kit for a time-separated application of the compositions is for example a cosmetic kit in which the compositions (A) and (B) are arranged in two separate containers.
- the consumer takes the composition (A) in its container and applies it on the skin. He then takes the composition (B) into the other container and also applies it to the skin, where the composition (A) is. He mixes the finger until a homogeneous composition that penetrates the epidermis for example.
- the invention also relates to the use of the kit as described above for the preparation of a cosmetic, dermo-pharmaceutical, pharmaceutical or food product.
- the active agent (s) of said product correspond to the active agents of the liquid heart of the capsule of the composition (A) and optionally of the composition (B).
- the invention also relates to a process for the preparation of a cosmetic, dermo-pharmaceutical, pharmaceutical or food product comprising at least one active agent, said process comprising the following steps:
- the invention more particularly relates to a method for preparing a cosmetic product comprising at least one cosmetic active agent, said process comprising the following steps:
- compositions (A) and (B) of the kit according to the invention comprising at least one cosmetic active agent
- the products prepared by this process are homogeneous compositions devoid of gel coat residues. They can have very different aspects and textures according to the compositions (A) and (B) used. It is thus possible to obtain a serum, a cream, a gel or a yogurt for example.
- the mixing time depends on the characteristics of the compositions of the kit and is generally less than one hour, advantageously less than 30 min, and preferably less than 10 min. This mixing time shall be reasonable in relation to the intended use of the kit.
- the invention also relates to a method of non-therapeutic cosmetic treatment of the skin comprising a step of applying to the skin at least one layer of the cosmetic product that can be obtained by the preparation method described above.
- the invention further relates to the cosmetic use of the cosmetic product obtainable by the preparation method described above.
- the invention also relates to a non-therapeutic cosmetic treatment method for the skin comprising the following steps:
- Figure 1 is a large-scale view, in section along a median vertical plane of a so-called “simple” capsule of the composition (A) of the kit according to the invention.
- FIG. 2 is a large scale view, in section along a median vertical plane of a capsule called "complex" of the composition (A) of the kit according to the invention.
- a single capsule 10 of the composition (A) of the kit according to the invention comprises a liquid core 12 consisting of a single internal phase and a gelled envelope 14 encapsulating the entire outer surface of the liquid core 12 to retain the liquid heart 12.
- a complex capsule 16 of the composition (A) of the kit according to the invention comprises a liquid core 18 which has an intermediate drop 20 of an intermediate phase, and a plurality of internal drops 22 of an internal phase disposed in the intermediate drop 20.
- the capsule 16 further comprises a gelled envelope 24 encapsulating the entire outer surface of the intermediate drop 20.
- Table 1 indicates the composition of the gel 1, the percentage by weight of each constituent is given relative to the total mass of the gel.
- Xanthan was first dispersed in the glycols (glycerol and propanediol) by stirring with a paddle stirrer. The actives, preservatives, perfumes and dyes were then added. The water was finally added and the whole was mixed by a paddle stirrer for about 1 hour. Gel 1 was thus obtained.
- glycols glycerol and propanediol
- Gel 1 is transparent. It has a viscosity of 1.5 Pa.s.
- the viscosity was measured at 10 revolutions / min by the method using a Brookfield type viscometer described above.
- Table 2 indicates the composition of the gel 2, the percentage by weight of each constituent is given relative to the total mass of the gel.
- Xanthan and hyaluronic acid were first dispersed in the glycols (glycerol and propanediol) by stirring with a paddle stirrer.
- the oligogeline was then added and stirring continued for about 30 minutes.
- water and ethanol were added and the whole was mixed by a paddle stirrer for about 2 hours. Gel 2 was thus obtained.
- the gel 2 is transparent. It has a viscosity of 9.5 Pa.s.
- Table 3 shows the composition of the capsules of series 1. The mass percentage of each constituent is given in relation to the total mass of the phase in which it is located and with respect to the total mass of a capsule.
- the method of manufacturing capsules is based on the concentric coextrusion of two solutions, in particular described in international application WO 2010/063937, to form double drops.
- the capsules of the series 1 were thus obtained according to the following stages: separate conveying in a double jacket of the first liquid solution (IF) and the second liquid solution (OF);
- each drop comprising a central core formed of first solution (IF) and a peripheral film formed of second solution (OF), completely covering the central core;
- Example 2.2 Preparation of liquid core complex capsules comprising an oily internal phase drop (IF) suspended in an aqueous intermediate phase (MF) (series 2)
- Table 4 indicates the composition of the capsules of series 2. The mass of each constituent is indicated.
- the capsules of series 2 were obtained according to the following steps:
- Example 2.3 Preparation of liquid core complex capsules comprising an internal drop of aqueous phase (IF) suspended in an oily intermediate phase (MF) (series 3)
- Table 5 indicates the composition of the capsules of series 3. The mass percentage of each phase is given relative to the total mass of the capsule and the weight percentage of each constituent is given relative to the total mass of the phase in which it is and relative to the total mass of a capsule.
- Rhodicare was added to the water with magnetic stirring. The solution was stirred for at least 2 hours to ensure that the solution was homogeneous. The asset then added to this solution.
- the capsules of series 3 were obtained according to the following stages:
- Example 2.2 60 g of complex capsules of series 2 (Example 2.2) were added to 40 g of gel 2 (Example 1.2) with planetary stirring using a three-dimensional turbulence.
- Table 6 indicates the composition (B) No. 1, the percentage by weight of each constituent is given relative to the total mass of the composition.
- Solution 2 was then added to Preparation 1, and mixed with a paddle stirrer until a homogeneous dispersion (about 45 minutes) was obtained. Thus solution 3 was obtained.
- citrate salts were added to the gelled solution 4 and the mixture was alternately heated to 75 ° C and mixed by a paddle stirrer.
- Active ingredients, preservatives, perfumes and dyes can be added at this stage.
- sweet almond oil, ethylhexyl palmitate, Micropearl and PEG-100 stearate (oil + emulsifiers) were successively weighed. The whole was then mixed and heated to 75 ° C until a homogeneous solution (about 30 min).
- thermosensitive molecules such as the active agents, the preservatives or the perfumes and dyes could be added and stirring continued until these molecules had completely dissolved in the water. emulsion obtained.
- the composition (B) No. 1 was thus obtained.
- Table 7 indicates the composition (B) No. 2, the mass percentage of each constituent of which is given in relation to the total mass of the composition.
- Solution 2 was then added to Preparation 1, and mixed with a paddle stirrer until a homogeneous dispersion was obtained (about 45 minutes). Thus solution 3 was obtained.
- citrate salts were added to the gelled solution 4 and the mixture was alternately heated to 75 ° C and mixed by a paddle stirrer.
- Active ingredients, preservatives, perfumes and dyes can be added at this stage.
- thermosensitive molecules such as the active agents, the preservatives or the perfumes and dyes could be added and stirring continued until these molecules had completely dissolved in the water. emulsion obtained. It was also at this stage that ethanol was added to avoid evaporation at the process temperatures used. There was thus obtained the composition (B) No. 2.
- Table 8 indicates the composition (B) No. 3, the percentage by weight of each constituent is given relative to the total mass of the composition.
- the salts (citric acid and sodium citrate dihydrate) and water were weighed separately. The salts were then added to the water and the solution was stirred until all the salts were completely dissolved. Assets, preservatives or even perfumes and dyes could be added at this stage.
- Table 9 indicates the composition (B) No. 4, the percentage by weight of each constituent is given relative to the total mass of the composition.
- the salts (citric acid and sodium citrate dihydrate) and water were weighed separately. The salts were then added to the water and the solution was stirred until all the salts were completely dissolved. Assets, preservatives or even perfumes and dyes could be added at this stage.
- Table 10 indicates the composition (B) No. 5, the weight percentage of each constituent of which is given relative to the total mass of the composition.
- the salts (citric acid and sodium citrate dihydrate) and water were weighed separately. The salts were then added to the water and the solution was stirred until all the salts were completely dissolved. Assets, preservatives or even perfumes and dyes could be added at this stage.
- composition (B) No. 5 The acrylic acid copolymer was then added to the previous solution and stirred with a paddle stirrer for about one hour to disperse the polymer in water. There was thus obtained the composition (B) No. 5.
- Table 1 1 indicates the composition (B) No. 6, the percentage by weight of each constituent is given relative to the total mass of the composition.
- Citric acid 1 00%
- the salts (citric acid and sodium citrate dihydrate) and water were weighed separately. The salts were then added to the water and the solution was stirred until all the salts were completely dissolved. Assets, preservatives or even perfumes and dyes could be added at this stage.
- Kit 1 comprises Composition (A) No. 1 (Example 3.1) and Composition (B) No. 1 (Example 4.1).
- compositions (A) and (B) of the kit 1 made it possible to obtain an emulsion-type product comprising 25% by weight of the composition (A) and 75% by weight of the composition ( B), opaque in appearance and having a viscosity of 5.5 Pa.s.
- the depolymerization kinetics are approximately 2 to 10 min.
- Viscosity was measured by the method using a Brookfield type viscometer described above.
- composition (A) 15 ml of composition (A) are in a jar, 60 ml of composition (B) are in a vial with a pump.
- Example 5.2 Kit for the Preparation and Use of a Cream Product (Kit 2) Kit 2 comprises Composition (A) No. 2 (Example 3.2) and Composition (B) No. 2
- compositions (A) and (B) of the kit 2 made it possible to obtain a cream-type product comprising 20% by weight of composition (A) and 80% by weight of composition (B). , opaque in appearance and viscosity equal to 38 Pa.s. The depolymerization kinetics are approximately 2 to 10 min.
- the viscosity was measured by the method using a viscometer of the type
- composition (A) 40 ml of composition (A) are in a pot and 10 ml of composition (B) are in a cup.
- Kit 3 comprises Composition (A) No. 3 (Example 3.3) and Composition (B) No. 3
- compositions (A) and (B) of the kit 3 made it possible to obtain a butter-like product comprising 15% by weight of composition (A) and 85% by weight of composition (B). , of aspect ranging from translucent to opaque and viscosity equal to 56 Pa.s. The depolymerization kinetics are approximately 2 to 10 min.
- Viscosity was measured by the method using a Brookfield type viscometer described above.
- Kit 4 comprises Composition (A) No. 4 (Example 3.4) and Composition (B) No. 4 (Example 4.4).
- compositions (A) and (B) of the kit 4 made it possible to obtain a product of the translucent solution type comprising 18% by weight of composition (A) and 82% by weight of composition (B). ), of translucent appearance and viscosity equal to 0.1 Pa.s.
- the depolymerization kinetics are approximately 2 to 10 min.
- Viscosity was measured by the method using a Brookfield type viscometer described above.
- Kit 5 comprises Composition (A) No. 5 (Example 3.5) and Composition (B) No. 5 (Example 4.5).
- compositions (A) and (B) of the kit 5 made it possible to obtain a very viscous gel-type product comprising 50% by weight of composition (A) and 50% by weight of composition ( B), of transparent appearance and viscosity equal to 26.7 Pa.s.
- the depolymerization kinetics are approximately 2 to 10 min.
- Viscosity was measured by the method using a Brookfield type viscometer described above.
- Example 5.6 Kit for the Preparation of a Viscous Gel Product (Kit 6)
- Kit 6 comprises Composition (A) No. 6 (Example 3.6) and Composition (B) No. 6 (Example 4.6).
- compositions (A) and (B) of the kit 6 made it possible to obtain a viscous gel-like product comprising 10% by weight of composition (A) and 90% by weight of composition (B). ), of aspect ranging from transparent to translucent and with a viscosity equal to 1 Pa.s.
- the depolymerization kinetics are approximately 10 to 30 min.
- Viscosity was measured by the method using a Brookfield type viscometer described above.
- compositions (A) of different viscosities were prepared to study the influence of viscosity on the physicochemical behavior of the composition (A) and capsules. For this, 40% by weight of capsules (those of Example 2.1) are mixed with 60% by weight of aqueous gel.
- the aqueous gels of different viscosities used correspond to the following formula, in which the proportion x of Xanthan is variable (typically from 0.1% to 2%) to obtain gels of different viscosities:
- the viscosity of the composition (A) allows the capsules to remain in suspension over a period of time greater than 1 month at room temperature.
- compositions (A) of variable viscosity were evaluated.
- the suspensivity of the capsules is evaluated by visual observation. Either the capsules are always uniformly distributed in the gel over the entire height of the bottle, and the gel is said to be “suspensive” (S). Either the capsules are unevenly distributed in the gel over the height of the bottle, and the gel is said to be “non-suspensory” (NS). In this second case, the capsules tend to "cream”, thus going back to the bottle of the bottle and creating a concentration gradient of capsules, starting from an absence of capsules in the bottom of the bottle, to a very high concentration of capsules in contact with each other in the top of the bottle.
- the viscosity of the composition (A) allows the capsules to remain intact during the transport of said composition (A).
- composition (A) 8 g are placed in a 10 ml stilliture packaging (Albéa reference).
- the stillide, containing the composition (A) is vigorously stirred manually (round-trip agitations).
- the state of the capsules is evaluated in terms of deformation of the capsules and the number of capsules broken by the following qualitative scale:
- the viscosity of the composition (A), when it is mixed with the depolymerizing composition (B), makes it possible to obtain a duration of depolymerization acceptable and compatible with a use of the cosmetic product obtained by mixing (A) and (B).
- composition (A) To 2.5 g of composition (A), a 30% blue citrate solution, further comprising 0.2% of xanthan, is added in a ratio of 1/20 or 1/10, ie 125 ⁇ -1 (ratio 1/20). ) or 250 ⁇ _ (ratio 1/10). The mixture is homogenized slowly (homogeneous blue color) without seeking to shear the capsules.
- the depolymerization time of the capsules is evaluated by qualitatively following the state (appearance, shape) of the capsules over time, after mixing the compositions (A) and (B).
- the homogeneity of the mixture and the presence of capsule envelope residues over time are simultaneously monitored qualitatively. These two parameters are evaluated using the following qualitative scales:
- the result of the depolymerization is considered acceptable according to the invention when the notation of the homogeneity of the mixture is less than or equal to 2 and those of the membrane residues is less than or equal to 2.
- the depolymerization time is considered acceptable according to the invention when it is less than or equal to 15 min. This therefore implies that the depolymerization, by its homogeneity aspects and envelope residues, is considered acceptable at 15 min or at lower times within the scope of the invention.
- the results are as follows
- the viscosity of the composition (A) makes it possible to obtain a cosmetic product (resulting from the mixture (A) + (B)) having a texture that is pleasant to the application.
- composition (B) of the following formula with a viscosity measured at 4.5 Pa.s (at 25 ° C. according to the method described above) is used:
- Pentylene glycol (Microcare® PTG) 2.0%
- the texture of the mixtures is no longer acceptable. Indeed, the increase in the viscosity of the gel leads to obtaining a tacky and sticky texture composition, which takes too long to penetrate the application.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1252119A FR2987741B1 (fr) | 2012-03-08 | 2012-03-08 | Kit comprenant deux compositions separees, notamment pour une application cosmetique |
PCT/EP2013/054785 WO2013132082A1 (fr) | 2012-03-08 | 2013-03-08 | Kit comprenant deux compositions séparées, notamment pour une application cosmétique |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2822530A1 true EP2822530A1 (fr) | 2015-01-14 |
Family
ID=47843315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13708186.5A Withdrawn EP2822530A1 (fr) | 2012-03-08 | 2013-03-08 | Kit comprenant deux compositions séparées, notamment pour une application cosmétique |
Country Status (5)
Country | Link |
---|---|
US (1) | US20150044263A1 (fr) |
EP (1) | EP2822530A1 (fr) |
CN (1) | CN104254312A (fr) |
FR (1) | FR2987741B1 (fr) |
WO (1) | WO2013132082A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150031646A1 (en) * | 2013-07-25 | 2015-01-29 | Ming-Chen Lee | Carrier enhancing absorption of medication |
FR3029785B1 (fr) * | 2014-12-16 | 2017-01-27 | Capsum | Dispersions stables comprenant des gouttes d'agent parfumant |
FR3031914B1 (fr) * | 2015-01-27 | 2019-06-07 | Calyxia | Procede d'encapsulation |
WO2017075074A1 (fr) * | 2015-10-26 | 2017-05-04 | The Procter & Gamble Company | Microcapsules et compositions assurant la libération contrôlée de principes actifs |
FR3052034B1 (fr) | 2016-06-01 | 2019-06-14 | Capsum | Dispositif de conditionnement et de distribution d'une composition, notamment cosmetique, resultant de la mise en oeuvre d'au moins deux compositions |
FR3054127B1 (fr) | 2016-07-20 | 2019-08-16 | Capsum | Serie de capsules et procede de fabrication, composition cosmetique et traitement cosmetique. |
FR3057768B1 (fr) * | 2016-10-26 | 2018-12-07 | Capsum | Emulsions doubles comprenant une phase grasse gelifiee |
FR3072026B1 (fr) * | 2017-10-10 | 2019-10-25 | Capsum | Ensembles de particules, procedes de preparation et kits les comprenant |
FR3086866B1 (fr) * | 2018-10-05 | 2020-12-18 | Capsum | Kit comprenant deux compositions separees, notamment pour une application cosmetique |
DE102019201364A1 (de) | 2019-02-04 | 2020-08-06 | Beiersdorf Ag | Kosmetisches Produkt enthaltend Kapseln |
FR3127948B1 (fr) * | 2021-10-08 | 2024-10-18 | Snf Sa | Composition polymerique comprenant un polymere hydrosoluble enveloppe dans un autre polymere et son utilisation dans le domaine de la cosmetique et de la detergence |
FR3141854A1 (fr) * | 2022-11-14 | 2024-05-17 | Capsum | Composition solide comprenant au moins une cavité et au moins une matière première hydrophile incompatible et/ou instable |
FR3147712A1 (fr) | 2023-04-13 | 2024-10-18 | Capsum | Dispersion cosmétique stabilisée par suspension stérique |
FR3147713A1 (fr) | 2023-04-13 | 2024-10-18 | Capsum | Dispersion cosmétique stabilisée par suspension stérique |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2645439B1 (fr) * | 1989-04-07 | 1991-06-21 | Oreal | Procede de preparation de capsules d'alginate(s) particulierement adaptees a un usage cosmetique, appareil pour sa mise en oeuvre et composition cosmetique contenant lesdites capsules |
JP2849437B2 (ja) * | 1990-03-30 | 1999-01-20 | 東陽化成株式会社 | 乳化状の化粧品と医薬部外品 |
US5293885A (en) * | 1991-07-11 | 1994-03-15 | Johnson Products Co., Inc. | Hair relaxer and post-relaxer hair brightener system |
JP3313124B2 (ja) * | 1991-07-31 | 2002-08-12 | 森下仁丹株式会社 | 親水性物質を内容物とするシームレスカプセルおよびその製法 |
CA2122923C (fr) * | 1991-11-25 | 1999-01-19 | Roy L. Blank | Compositions pour lutter contre les rides de la peau et/ou l'atrophie cutanee |
FR2700952B1 (fr) * | 1993-01-29 | 1995-03-17 | Oreal | Nouvelles compositions cosmétiques ou dermopharmaceutiques sous forme de gels aqueux modifiés par addition de microsphères expansées. |
DE19933452A1 (de) * | 1999-07-16 | 2000-02-17 | Wella Ag | Verkapselte Duft- oder Wirkstoffe enthaltendes Haarkonditioniermittel in Gelform |
US6800277B2 (en) * | 2002-06-28 | 2004-10-05 | L'oreal, S.A. | Hair relaxer compositions with a visual indicator |
DE10306604A1 (de) * | 2003-02-18 | 2004-08-26 | Goldschmidt Ag | Kosmetische Zubereitungen mit Wirkstoffen in Mikrokapseln |
US20070275080A1 (en) * | 2003-10-31 | 2007-11-29 | Engineered Release Systems Inc. | Polymer-Based Microstructures |
US20060280795A1 (en) * | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
US7622132B2 (en) * | 2005-06-27 | 2009-11-24 | Elc Management, Llc | Encapsulated cosmetic composition |
NL1034260C2 (nl) * | 2007-08-16 | 2009-02-17 | Friesland Brands Bv | Ingekapselde eetbare vloeistoffen. |
US20110180445A1 (en) * | 2008-06-03 | 2011-07-28 | Marni Markell Hurwitz | Cosmetic tablets and capsules for direct delivery of active ingredients |
WO2009149374A2 (fr) * | 2008-06-06 | 2009-12-10 | Reveal Sciences, Llc | Système de chimie multi-pièce |
FR2939012B1 (fr) | 2008-12-01 | 2015-03-27 | Capsum | Procede de fabrication d'une serie de capsules, et serie de capsules associee |
FR2969920B1 (fr) * | 2010-12-31 | 2013-05-10 | Capsum | Capsule parfumante sans alcool |
FR2986165B1 (fr) * | 2012-01-31 | 2015-07-24 | Capsum | Procede de preparation de capsules rigidifiees |
-
2012
- 2012-03-08 FR FR1252119A patent/FR2987741B1/fr active Active
-
2013
- 2013-03-08 EP EP13708186.5A patent/EP2822530A1/fr not_active Withdrawn
- 2013-03-08 CN CN201380013175.XA patent/CN104254312A/zh active Pending
- 2013-03-08 US US14/383,148 patent/US20150044263A1/en not_active Abandoned
- 2013-03-08 WO PCT/EP2013/054785 patent/WO2013132082A1/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
AARON P. ESSER-KAHN ET AL: "Triggered Release from Polymer Capsules", MACROMOLECULES, vol. 44, no. 14, 6 July 2011 (2011-07-06), pages 5539 - 5553, XP055018547, ISSN: 0024-9297, DOI: 10.1021/ma201014n * |
Also Published As
Publication number | Publication date |
---|---|
CN104254312A (zh) | 2014-12-31 |
US20150044263A1 (en) | 2015-02-12 |
FR2987741A1 (fr) | 2013-09-13 |
WO2013132082A1 (fr) | 2013-09-12 |
FR2987741B1 (fr) | 2014-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2822530A1 (fr) | Kit comprenant deux compositions séparées, notamment pour une application cosmétique | |
EP2370066B1 (fr) | Procede de fabrication d'une serie de capsules, et serie de capsules associee | |
WO2012089820A1 (fr) | Serie de capsules comprenant au moins une goutte de phase interne dans une goutte de phase intermediaire et procede de fabrication associe | |
US9604190B2 (en) | Method for preparing stiffened capsules | |
EP2885085B1 (fr) | Elément de délivrance d'une composition fluide, dispositif de distribution et procédé associés | |
FR3075049B1 (fr) | Composition aqueuse moussante comprenant de l’acide spiculisporique, un alkyl polyglycoside et un polysaccharide | |
WO2015071433A1 (fr) | Composition comprenant des capsules gélifiées stabilisées par un tampon | |
CA2307321A1 (fr) | Utilisation de nanofibrilles de cellulose essentiellement amorphes associees a au moins un compose organique polyhydroxyle dans des formulations cosmetiques | |
WO2013132083A1 (fr) | Dispersion comprenant des corps dispersés, chacun comportant une goutte interne et une membrane | |
EP3487476A1 (fr) | Série de capsules et procédé de fabrication, composition cosmétique et traitement cosmétique | |
WO2019002579A1 (fr) | Composition triphasique | |
WO2011086331A2 (fr) | Procédé de fabrication de capsules avec une hauteur de chute contrôlée. | |
WO2015075074A1 (fr) | Procédé de préparation de capsules comprenant un coeur liquide et une coque externe | |
FR3086866A1 (fr) | Kit comprenant deux compositions separees, notamment pour une application cosmetique | |
FR2969920A1 (fr) | Capsule parfumante sans alcool | |
FR3071730A1 (fr) | Composition comprenant une phase aqueuse continue liquide et une phase dispersee sous forme de gouttes | |
FR3072026B1 (fr) | Ensembles de particules, procedes de preparation et kits les comprenant | |
FR2996752A1 (fr) | Utilisation de de billes cosmetiques, emballage et billes cosmetiques associes. | |
FR3071728B1 (fr) | Composition adaptee pour former un radeau gastrique gelifie | |
WO2024213706A1 (fr) | Dispersion cosmétique stabilisée par suspension stérique | |
WO2023094513A1 (fr) | Emulsion millimétrique bi-phasique | |
WO2014195268A1 (fr) | Vanne à boisseau, dispositif de dosage d'un fluide et procédé de dosage associés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140826 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SANTANACH CARRERAS, ENRIC Inventor name: GOUTAYER, MATHIEU Inventor name: COURTEMANCHE, MARION Inventor name: BARDON, SEBASTIEN Inventor name: BIBETTE, JEROME Inventor name: DELMAS, THOMAS |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20170210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180809 |